UZEDY Drug Patent Profile
✉ Email this page to a colleague
When do Uzedy patents expire, and what generic alternatives are available?
Uzedy is a drug marketed by Teva and is included in one NDA. There are nine patents protecting this drug.
This drug has seventy-six patent family members in thirty-four countries.
The generic ingredient in UZEDY is risperidone. There are thirty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the risperidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uzedy
A generic version of UZEDY was approved as risperidone by APOTEX INC on September 15th, 2008.
Summary for UZEDY
| International Patents: | 76 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for UZEDY |
| What excipients (inactive ingredients) are in UZEDY? | UZEDY excipients list |
| DailyMed Link: | UZEDY at DailyMed |
Pharmacology for UZEDY
| Drug Class | Atypical Antipsychotic |
Anatomical Therapeutic Chemical (ATC) Classes for UZEDY
US Patents and Regulatory Information for UZEDY
UZEDY is protected by nine US patents and one FDA Regulatory Exclusivity.
Patents protecting UZEDY
Risperidone biodegradable implant
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Drug-containing implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SCHIZOPHRENIA
Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SCHIZOPHRENIA
Risperidone-containing PLA:PGA implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Biodegradable drug delivery compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Risperidone-containing implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SCHIZOPHRENIA
Drug-containing implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Drug-containing PLA implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Drug-containing implants and methods of use thereof
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting UZEDY
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-004 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-006 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Teva | UZEDY | risperidone | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 213586-005 | Apr 28, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for UZEDY
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Laboratorios Farmacéuticos Rovi, S.A. | Okedi | risperidone | EMEA/H/C/005406 Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. |
Authorised | no | no | no | 2022-02-14 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for UZEDY
See the table below for patents covering UZEDY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005070332 | ⤷ Try a Trial | |
| Spain | 2939744 | ⤷ Try a Trial | |
| Portugal | 2658525 | ⤷ Try a Trial | |
| Canada | 2822854 | COMPOSITIONS BIODEGRADABLES D'ADMINISTRATION DE MEDICAMENTS (BIODEGRADABLE DRUG DELIVERY COMPOSITIONS) | ⤷ Try a Trial |
| Japan | 5405825 | ⤷ Try a Trial | |
| Eurasian Patent Organization | 201390783 | БИОРАЗЛАГАЕМЫЕ КОМПОЗИЦИИ ДЛЯ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UZEDY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0196132 | 94C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
